Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human Phase 1 single-ascending dose study of XmAb942 for the treatment of inflammatory bowel diseases (IBD)

Next Previous
X
Search
Trial Profile

A first-in-human Phase 1 single-ascending dose study of XmAb942 for the treatment of inflammatory bowel diseases (IBD)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XmAb 942 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 11 Sep 2024 New trial record
    • 09 Sep 2024 According to a Xencor media release, company anticipates dosing the first subject in a first-in-human, single-ascending dose study of XmAb942 in the fourth quarter of 2024, with interim data during the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top